- Key Release /Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…
- Media Release /First-line tislelizumab plus chemotherapy showed median overall survival of 17.2 months versus 10.6 months for chemotherapy and reduced risk of death by 34% in patients with advanced esophageal…
- Media Release /Production and phased deliveries of patient doses resumed in early June Screening and enrollment have restarted for 177Lu-PSMA-617 and Lutathera® clinical trials Expanding radioligand therapy…
- Media Release /EUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwideNew project brings total planned investment into…
- Media Release /Results from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (…
- Story /
The disease hobbles families and economies.
- Story /
In October 2013, we created a new, full-time position to lead our CR efforts. Juergen Brokatzky-Geiger, formerly Global Head of Human Resources and a member of the Executive Committee, took on this role effective in February 2014.
- Story /
Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.
- Story /
Ann Aerts has stared death in the eye. The head of the non-profit Novartis Foundation lost colleagues when she was serving as an emergency medicine physician on a medical mission in a dangerously unstable country.
- Story /
After 40 years of working in information technology, Jim Barrington took a partial retirement from his job as Novartis’ chief information officer and started looking for new ways to apply his skills.
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 264
- › Next page